SPEAKERS

SAMPLE OF KEYNOTE SPEAKERS AND THEIR CASE STUDIES

Allan Christian SHAW

Corporate Vice President

CASE STUDY / DAY 1

Perspectives on Digitalisation of Early Research in Novo Nordisk

Different aspects of the digitalization journey of early research in Novo Nordisk are presented, covering the opportunities for improving innovation and process efficiency, as well as the encountered challenges and learnings, done

  • Novo Nordisk’s early research at a glance and why digitalization efforts rapidly became important
  • Conducting digital transformation in a highly dynamic research environment
  • Examples of impact on innovation, gain of efficiencies and ways of working
  • Challenges: From a technology and cultural perspective
CASE STUDY / DAY 1

Using Data, AI and ML to Accelerate Pharma Omni-Channel Strategy and HCP Engagement

Discover how customer insights, journey maps, and content generation are being powered through a new digital strategy.

  • The value AI, MA and Big Data can bring to the HCP engagement
  • The digital strategy challenge
  • Real life case of “data challenge”
  • How do we get there?

Shay WEISS

Director of Novartis Omnichannel Engineering

SUMMIT WILL HOST SPEAKERS FROM THE WORLD’S LEADING COMPANIES

Shay WEISS

Director of Novartis Omnichannel Engineering

CASE STUDY DAY 1

Using Data, AI and ML to Accelerate Pharma Omni-Channel Strategy and HCP Engagement

Discover how customer insights, journey maps, and content generation are being powered through a new digital strategy.

• The value AI, MA and Big Data can bring to the HCP engagement
• The digital strategy challenge
• Real life case of “data challenge”
• How do we get there?

Meni STYLIADOU

VP, Distinguished Fellow Data Sciences Institute, Research and Development

CASE STUDY DAY 2

H2O: Creating Ecosystem to Empower Patients to Monitor Their Outcomes in a Standardized Way Through Digital Technologies

It is universally accepted that the patient’s voice matters. However, unless captured in a standardized manner, it is often misunderstood or ignored. The H2O consortium of 26 partners including leading academic hospitals, patient organisations, pharmaceutical companies as well as public authorities came together to do three things:
a. create 'common language' for patients and HCPs through standardized PROs that can be used in clinical practice;
b. partner with technology providers active in digital health to implement this common language in clinical practice in several countries;
c. introduce a governance model to ensure that patients remain in control of their data.

• What does it mean a 'common language' for patients and HCPs and why do we need it?
• How can one create such a 'common language'?
• How does this ecosystem work?
• How would the governance look like? And how does one create the necessary trust?
• What is the value created for the various stakeholders?

Allan Christian SHAW

Corporate Vice President

CASE STUDY DAY 1

Perspectives on Digitalisation of Early Research in Novo Nordisk

Different aspects of the digitalization journey of early research in Novo Nordisk are presented, covering the opportunities for improving innovation and process efficiency, as well as the encountered challenges and learnings, done

• Novo Nordisk’s early research at a glance and why digitalization efforts rapidly became important
• Conducting digital transformation in a highly dynamic research environment
• Examples of impact on innovation, gain of efficiencies and ways of working
• Challenges: From a technology and cultural perspective

Elcie CHAN

EU Commercial Director – Digital Health

CASE STUDY DAY 2

Pharma-Digital Health Partnerships: What Does It Take to Partner to Achieve Success Globally?

There are many Pharma and Digital Health partnerships today, but only a few of these partnerships span multiple regions. What does it take to partner to reach commercial success globally? This presentation will provide a perspective on the key considerations for Global partnership models, with a focus on the U.S. and Europe, and the implications for establishing a successful DTx business across multiple markets.

• The implication of regional differences in Pharma-Digital Health partnership models
• Opportunities and challenges in preparing for Global success
• The impact of organisational structure, culture, and mindset (as individual companies and as partners) on strategy through the execution

Jennie MEDIN

Head Real World Science & Analytics

CASE STUDY DAY 2

Real World Data for Clinical Practice Change

Real World Data (RWD) is a key enabler to move towards personalized engagement with stakeholders with the aim to improve health care and patient outcomes. In this session, we will discuss how RWD can be used to understand patient journeys, focus on medical strategies and personalize customer interactions.

• Real World Data as an enabler
• Clinical Practice Change
• Localized data

Meni STYLIADOU

VP, Distinguished Fellow Data Sciences Institute, Research and Development

CASE STUDY / DAY 2

H2O: Creating Ecosystem to Empower Patients to Monitor Their Outcomes in a Standardized Way Through Digital Technologies

It is universally accepted that the patient’s voice matters. However, unless captured in a standardized manner, it is often misunderstood or ignored. The H2O consortium of 26 partners including leading academic hospitals, patient organisations, pharmaceutical companies as well as public authorities came together to do three things:

a. create ‘common language’ for patients and HCPs through standardized PROs that can be used in clinical practice;
b. partner with technology providers active in digital health to implement this common language in clinical practice in  several countries;
c. introduce a governance model to ensure that patients remain in control of their data.

  • What does it mean a ‘common language’ for patients and HCPs and why do we need it?
  • How can one create such a ‘common language’?
  • How does this ecosystem work?
  • How would the governance look like? And how does one create the necessary trust?
  • What is the value created for the various stakeholders?
CASE STUDY / DAY 2

Real World Data for Clinical Practice Change

Real World Data (RWD) is a key enabler to move towards personalized engagement with stakeholders with the aim to improve health care and patient outcomes. In this session, we will discuss how RWD can be used to understand patient journeys, focus on medical strategies and personalize customer interactions.

  • Real World Data as an enabler
  • Clinical Practice Change
  • Localized data

Jennie MEDIN

Head Real World Science & Analytics

Elcie CHAN

EU Commercial Director – Digital Health

CASE STUDY / DAY 2

Pharma-Digital Health Partnerships: What Does It Take to Partner to Achieve Success Globally?

There are many Pharma and Digital Health partnerships today, but only a few of these partnerships span multiple regions. What does it take to partner to reach commercial success globally? This presentation will provide a perspective on the key considerations for Global partnership models, with a focus on the U.S. and Europe, and the implications for establishing a successful DTx business across multiple markets.

  • The implication of regional differences in Pharma-Digital Health partnership models
  • Opportunities and challenges in preparing for Global success
  • The impact of organisational structure, culture, and mindset (as individual companies and as partners) on strategy through the execution

Well organised event with professional speeches, very informative, helps to enhance knowledge and experience.

– Head of International Medical Affairs, Servier

Event programme

Fill your details in the form and we will
send you the whole brochure filled with all details

Your copy of the brochure is prepared.

Inside you will find

  • What keynote speakers will be taking part in the exclusive speaking panel
  • What Case Studies will be discussed by our senior corporate speakers
  • The minute by minute breakdown of the conference